Ariad Pharmaceuticals, Inc. (Nasdaq:ARIA) rose 30 percent to end the week at $8.99 a share after an article in the U.K news website, Mail Online, cited unnamed “dealers” who said Indianapolis-based Eli Lilly & Co. reportedly offered to pay $20 a share for the company. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $9.44 in last session, and closed at $7.91, while the day range of stock is $7.57 – $9.74. The stock showed a positive weekly performance of 14.64%.
Pfizer Inc. (NYSE:PFE) announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer (NSCLC). Pfizer Inc. (NYSE:PFE) stock opened at $30.04, in last session and closed at $29.66, by losing -1.43%. The 52 week range of the stock is $26.76 – $32.50. Company’s market capitalization is $192.23 billion.
Merck & Co., Inc. (NYSE:MRK) was upgraded by research analysts at Morgan Stanley to an “overweight” rating in a report released on Monday, Stock Ratings Network.com reports. Merck & Co., Inc. (NYSE:MRK) stock advanced 1.06% and finished the last session at $52.53. The EPS of the stock remained 1.51. Company’s market capitalization is $153.73 billion.
The day-of stock reaction to Friday’s Bristol-Myers Squibb Co (NYSE:BMY) financial and pipeline report was not a good one—Bloomberg reported shares plunged to their lowest level in 17 months. But longer-view analysts are not in a punishing mood, despite the headline news that the company did not share data about its experimental immuno-oncology combination of Yervoy and nivolumab for non-small cell lung cancer (NSCLC), deferring the data read-out until the May ASCO meeting. Bristol-Myers Squibb Co (NYSE:BMY) stock opened the session at $51.08, and closed the session at $49.72. The 52 week range of the stock remained $35.77 – $56.83 and the day range was $49.45 – $51.09.
Leave a Reply